1. Home
  2. PUMP vs GERN Comparison

PUMP vs GERN Comparison

Compare PUMP & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo ProPetro Holding Corp.

PUMP

ProPetro Holding Corp.

HOLD

Current Price

$17.12

Market Cap

1.0B

Sector

Energy

ML Signal

HOLD

Logo Geron Corporation

GERN

Geron Corporation

HOLD

Current Price

$1.27

Market Cap

782.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PUMP
GERN
Founded
2007
1990
Country
United States
United States
Employees
N/A
258
Industry
Oilfield Services/Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
782.7M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
PUMP
GERN
Price
$17.12
$1.27
Analyst Decision
Buy
Hold
Analyst Count
7
3
Target Price
$14.14
$2.17
AVG Volume (30 Days)
5.0M
14.8M
Earning Date
04-30-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
100.76
N/A
EPS
N/A
N/A
Revenue
$1,269,158,000.00
N/A
Revenue This Year
N/A
$26.91
Revenue Next Year
$15.61
$43.75
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$4.51
$1.04
52 Week High
$18.50
$2.01

Technical Indicators

Market Signals
Indicator
PUMP
GERN
Relative Strength Index (RSI) 56.35 33.75
Support Level $14.90 $1.24
Resistance Level N/A $1.29
Average True Range (ATR) 0.89 0.09
MACD 0.02 -0.02
Stochastic Oscillator 59.76 12.38

Price Performance

Historical Comparison
PUMP
GERN

About PUMP ProPetro Holding Corp.

ProPetro Holding Corp is a Texas-based oilfield services company. It provides hydraulic fracturing, wireline, and other complementary services to oil and gas companies engaged in the exploration and production of North American oil and natural gas resources. The company focused on the Permian Basin. The operating segments of the company are hydraulic fracturing which generates key revenue, wireline, cementing, and power generation service.

About GERN Geron Corporation

Geron Corp is a biopharmaceutical company focused on blood cancers. Its telomerase inhibitor, RYTELO (imetelstat), is approved in the United States and European Union for certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia. RYTELO inhibits telomerase activity in malignant stem and progenitor cells, which may reduce abnormal cell proliferation while supporting the production of healthy cells. It is also conducting a Phase 3 trial of imetelstat in patients with JAK-inhibitor-refractory or relapsed myelofibrosis (R/R MF) and studies in other hematologic malignancies. The company operates as a single segment, being the development of therapeutic products for oncology.

Share on Social Networks: